Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.45 | N/A | +34.88% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.45 | N/A | +34.88% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding market conditions and the company's performance. They reiterated their commitment to long-term strategies.
Management highlighted ongoing challenges in the current market environment.
They emphasized the importance of focusing on long-term goals despite short-term setbacks.
Nektar Therapeutics reported a wider-than-expected loss per share, which was a positive surprise compared to expectations. However, the lack of revenue data and guidance contributed to a slight decline in the stock price by 1.1%. Investors may be concerned about the company's future prospects given the current market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARATHON PETE CORP
Aug 3, 2020